SUMMARY
- Transcell Biologics has secured an undisclosed sum of investment from Quantiphi and IAN Group.
- The funds will be used for the broadening of its clientele and the deployment of DART)
- DART is a technology that facilitates animal-free testing methods, integrating hMPS technology with AI/ML in silico platform configurations.
Hyderabad-based biotechnology firm Transcell Biologics has secured an undisclosed sum of investment from Boston-based Quantiphi and IAN Group.
The funds will be used for the broadening of its clientele and the deployment of Digital Animal Replacement Technology (DART) as a comprehensive enterprise solution for the international bio and pharmaceutical sectors, as announced in a press release.
Established in 2009 by Subadra Dravida, Transcell Biologics is at the forefront of enhancing stem cell yield while maintaining pluripotency and functionality, alongside offering a proprietary methodology and expanding its scope of applications for stem cell technologies.
The company describes DART as a technology that facilitates animal-free testing methods, integrating human MicroPhysiological Systems (hMPS) technology with Artificial Intelligence/Machine Learning (AI/ML) in silico platform configurations. This integration aims to streamline and automate bioassay processes, ensuring the generation of statistically compliant reports. The solution is curated to address safety and efficacy concerns related to drugs and vaccines intended for human use.
Transcell Biologics has observed considerable interest in DART within the Indian markets, with biopharmaceutical companies integrating its enterprise solution into their pivotal programs. The firm is set to further its clientele in the United States, Europe, and Japan.
